Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Jun Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2362-5359; OpenAlex author ID A5100450174. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: none · 2021: 3 papers · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 7

  1. Survival and pathological response in pancreatic ductal adenocarcinoma after preoperative therapy with PD-1 blockade plus chemoradiotherapy followed by surgica… Co-author DOI 10.1080/07853890.2025.2541314↗
  2. Transcatheter Arterial Infusion Combined With Radioactive Particles in the Treatment of Advanced Body/Tail Pancreatic Cancer: A Retrospective Cohort Study. Co-author DOI 10.1097/mpa.0000000000001851↗
  3. LncRNA PWAR6 regulates proliferation and migration by epigenetically silencing YAP1 in tumorigenesis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/jcmm.16480↗
  4. Laminin‑332 mediates proliferation, apoptosis, invasion, migration and epithelial‑to‑mesenchymal transition in pancreatic ductal adenocarcinoma. First author DOI 10.3892/mmr.2020.11649↗
  5. Long non-coding RNA CUDR promotes malignant phenotypes in pancreatic ductal adenocarcinoma via activating AKT and ERK signaling pathways. Co-author DOI 10.3892/ijo.2018.4574↗
  6. Overexpression of α3, β3 and γ2 chains of laminin-332 is associated with poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2018.8678↗
  7. Overexpression of β3 Chains of Laminin-332 is Associated With Clinicopathologic Features and Decreased Survival in Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1097/pai.0000000000000115↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Caiqun Huang · 1 shared paper, 2021 · strength 0.28
  2. Song Zhang · 1 shared paper, 2025 · strength 0.21
  3. Huizi Sha · 1 shared paper, 2025 · strength 0.21
  4. Juan Du · 1 shared paper, 2025 · strength 0.21
  5. Yudong Qiu · 1 shared paper, 2025 · strength 0.21
  6. Elyar Abaydulla · 1 shared paper, 2025 · strength 0.21
  7. Shanshan Shen · 1 shared paper, 2025 · strength 0.21
  8. Hao Cheng · 1 shared paper, 2025 · strength 0.21
  9. Dongkai Zhou · 2 shared papers, 2015–2018 · strength 0.14
  10. Shanshan Huang · 1 shared paper, 2021 · strength 0.12
  11. Junhe Li · 1 shared paper, 2021 · strength 0.12
  12. Jianping Xiong · 1 shared paper, 2021 · strength 0.12
  13. Yuliang Li · 1 shared paper, 2021 · strength 0.10
  14. Wujie Wang · 1 shared paper, 2021 · strength 0.10
  15. Xiaoping Zhang · 1 shared paper, 2021 · strength 0.10
  16. Shilong Han · 1 shared paper, 2021 · strength 0.10
  17. Huirong Xu · 1 shared paper, 2021 · strength 0.10
  18. Maoquan Li · 1 shared paper, 2021 · strength 0.10
  19. Shian Yu · 1 shared paper, 2018 · strength 0.09
  20. Xiangui Hu · 1 shared paper, 2018 · strength 0.08
  21. An‐An Liu · 1 shared paper, 2018 · strength 0.08
  22. Xing Liang · 1 shared paper, 2018 · strength 0.08
  23. Lixing Zhan · 1 shared paper, 2018 · strength 0.08
  24. Chenghao Shao · 1 shared paper, 2018 · strength 0.08
  25. Shusen Zheng · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.